Physician profile
Ling Lu
NPI 1447562376
$10,843.91
in general payments reported to CMS, 2019-2025
25 companies · $2,700 in 2025
The $2,700 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $531 · 2021: $1,497 · 2022: $1,957 · 2023: $365 · 2024: $2,224 · 2025: $2,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,288.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,229.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,037.24 | 2019-2025 | Otezla, Evenity, Repatha |
| Esperion Therapeutics, INC. | $1,601.12 | 2021-2024 | Nexletol |
| Madrigal Pharmaceuticals | $638.83 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $617.54 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $585.75 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $454.61 | 2024-2025 | Vemlidy |
| Abbvie INC. | $449.99 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $445.00 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.59 | 2020-2022 | |
| Lilly USA, LLC | $201.92 | 2020-2024 | Mounjaro |
| Novo Nordisk INC | $181.20 | 2020-2022 | |
| Globus Medical, INC. | $165.85 | 2025 | Senza |
| Amarin Pharma, INC. | $158.99 | 2020-2022 | |
| Angiodynamics, INC. | $125.00 | 2024 | Nanoknife |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $109.16 | 2024-2025 | Zoryve |
| Ibsa Pharma INC. | $91.67 | 2021-2022 | |
| Pfizer INC. | $70.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.71 | 2022-2024 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $47.15 | 2025 | Myfembree, Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $45.68 | 2022 | |
| Exact Sciences Corporation | $39.28 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $37.25 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $33.19 | 2022-2023 | Linzess |
| Vbi Vaccine (Delaware) INC. | $18.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.